- Home
- SNTI vs NXC Comparison
SNTI vs NXC Comparison
Compare SNTI & NXC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SNTI
- NXC
- Stock Information
- Founded
- SNTI 2016
- NXC 1992
- Country
- SNTI United States
- NXC United States
- Employees
- SNTI N/A
- NXC N/A
- Industry
- SNTI Biotechnology: Pharmaceutical Preparations
- NXC Investment Managers
- Sector
- SNTI Health Care
- NXC Finance
- Exchange
- SNTI Nasdaq
- NXC Nasdaq
- Market Cap
- SNTI 85.3M
- NXC 81.7M
- IPO Year
- SNTI N/A
- NXC N/A
- Fundamental
- Price
- SNTI $3.56
- NXC $12.75
- Analyst Decision
- SNTI Strong Buy
- NXC
- Analyst Count
- SNTI 1
- NXC 0
- Target Price
- SNTI $12.00
- NXC N/A
- AVG Volume (30 Days)
- SNTI 25.9K
- NXC 17.5K
- Earning Date
- SNTI 05-06-2025
- NXC 01-01-0001
- Dividend Yield
- SNTI N/A
- NXC 3.97%
- EPS Growth
- SNTI N/A
- NXC N/A
- EPS
- SNTI N/A
- NXC 0.19
- Revenue
- SNTI N/A
- NXC N/A
- Revenue This Year
- SNTI N/A
- NXC N/A
- Revenue Next Year
- SNTI N/A
- NXC N/A
- P/E Ratio
- SNTI N/A
- NXC $70.47
- Revenue Growth
- SNTI N/A
- NXC N/A
- 52 Week Low
- SNTI $1.52
- NXC $11.86
- 52 Week High
- SNTI $16.94
- NXC $13.70
- Technical
- Relative Strength Index (RSI)
- SNTI 58.08
- NXC 46.16
- Support Level
- SNTI $3.04
- NXC $12.66
- Resistance Level
- SNTI $3.25
- NXC $12.90
- Average True Range (ATR)
- SNTI 0.23
- NXC 0.11
- MACD
- SNTI 0.04
- NXC -0.01
- Stochastic Oscillator
- SNTI 89.83
- NXC 21.43
About SNTI Senti Biosciences Inc.
Senti Biosciences Inc is a clinical-stage biotechnology company developing next-generation cell and gene therapies engineered with its gene circuit platform technologies for patients living with incurable diseases. The product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications. The company product candidates include SENTI-202, a Logic Gated off-the-shelf CAR-NK cell therapy designed to target and eliminate cancer cells while sparing the healthy bone marrow; and SENTI-301A for the treatment of hepatocellular carcinoma.
About NXC Nuveen California Select Tax-Free Income Portfolio
Nuveen CA Select Tax Free Income Port is a diversified closed-end management investment company. Its objective is to provide stable dividends exempt from both regular federal and California income taxes, consistent with the preservation of capital by investing in municipal obligations.